Promomed Group received marketing authorization certificate for a medicinal product with nadroparin calcium as active ingredient. Nadroparin is a low molecular weight heparin. It has a high antithrombotic potential and helps to reduce blood viscosity. The properties of ThromboForce® Forte allow it to be used for the treatment of thrombosis and thromboembolism of various etiologies, including those associated with COVID-19.
Such serious and life-threatening conditions as deep vein thrombosis and pulmonary embolism (PE) are among the most important problems of modern medicine. These diseases may be caused by damage of the inner walls of vessels, disturbance of venous blood circulation, increased formation of blood clots, or a combination of these conditions. Activation of blood coagulation processes plays the main role in the formation of blood clots, leading to the formation of a fibrin network in which individual erythrocytes and leukocytes get stuck and so-called platelet-fibrin clot (platelet plug) is formed.
Thrombosis and thromboembolism have become a real challenge for the global healthcare system, as they are a frequent complication in patients, including young patients without chronic diseases.
Kira Zaslavskaya, Director for New Products at Promomed Group, comments:
Promomed is actively working to expand the portfolio of drugs for the complex therapy of COVID-19. The company is focused on solving global medical problems and saving lives, so this is one of our priority tasks. The introduction of Thromboforce Forte into clinical practice will expand the list of effective and safe drugs for the treatment of thrombosis and thromboembolism, which, among other things, are one of the most dangerous consequences of coronavirus infection.
Nadroparin, the active substance of the drug, is a low molecular weight heparin, which has good bioavailability, low binding to plasma proteins, an optimal half-life, and therefore its anticoagulant effect is more predictable.
Thromboforce® Forte is available in the form of solution for subcutaneous administration. It contains 19,000 anti-Xa IU/ml.
The anti-COVID portfolio of Promomed Group already includes drug products for COVID-19 of any severity, modern antibiotics and effective anticoagulants. Now it is represented by such products as Areplivir®, Enoparin® and others.